You are here
Acknowledging there was room for improvement, the authors of PCI appropriate use criteria (AUC) have applied lessons from the last set of guidelines in a revision scheduled for publication this year, a member of the writing committee said.
When comparing transcatheter and surgical aortic valve replacements, findings presented at the American College of Cardiology scientific sessions noted that there were no differences in death, stroke, or MI at one year. However, there were some differences in outcomes, leaving neither on top.
Analyzing the link between obesity and arrhythmia, LEGACY confirmed that among obese patients, weight loss greatly influenced freedom from atrial fibrillation, particularly among those who lost weight and maintained it. However, more than 5 percent fluctuation in weight over one year increased patient risks.
Performing an ablation along with mitral valve surgery is more likely to keep cardiac patients free of persistent atrial fibrillation (AF) at one year, according to results unveiled March 16 at the American College of Cardiology scientific session. But it also increased the risk of needing a pacemaker.
Ami Bhatt, MD, co-director of the adult congenital heart disease program at Massachusetts General Hospital in Boston, shared her thoughts with Cardiovascular Business about sessions at the American College of Cardiology’s scientific session that she considered most exciting.
TOTAL may not totally spell the end of routine manual thrombectomy with PCI, but it should make interventional cardiologists think twice about using it with STEMI patients. The large, international trial showed no clinical benefit and possible harm.
The human monoclonal antibody evolocumab plus standard therapy not only lowered low-density lipoprotein cholesterol but it also cut the rate of cardiovascular events by about half compared with standard therapy alone, according to results presented March 15 at the American College of Cardiology scientific session.
High-risk patients with severe aortic stenosis had similar outcomes at five years in both arms of the PARTNER I trial, a finding that the presenter at the American College of Cardiology scientific session called a win for the intervention.
So it wasn’t a fluke. Two-year results from the CoreValve pivotal trial for high-risk patients with severe aortic stenosis reaffirmed that the transcatheter aortic valve replacement device is superior to standard surgery. The results were presented March 15 at the American College of Cardiology scientific session.
Jeffrey Cavendish, MD, of Kaiser Permanente in San Diego, shared his impressions of the first day of the American College of Cardiology’s (ACC) scientific session with Cardiovascular Business. His highlights touch on three Ps: prevention, PROMISE and PEGASUS.